Literature DB >> 23081814

Comparison of four assays for the detection of cryptococcal antigen.

M J Binnicker1, D J Jespersen, J E Bestrom, L O Rollins.   

Abstract

We compared the performance of four assays for the detection of cryptococcal antigen in serum samples (n = 634) and cerebrospinal fluid (CSF) samples (n = 51). Compared to latex agglutination, the sensitivity and specificity of the Premier enzyme immunoassay (EIA), Alpha CrAg EIA, and CrAg lateral flow assay (LFA) were 55.6 and 100%, 100 and 99.7%, and 100 and 99.8%, respectively, from serum samples. There was 100% agreement among the four tests for CSF samples, with 18 samples testing positive by each of the assays.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23081814      PMCID: PMC3535868          DOI: 10.1128/CVI.00446-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  7 in total

1.  Evaluation of three commercial latex agglutination kits and a commercial enzyme immunoassay for the detection of cryptococcal antigen.

Authors:  Ngolela Esther Babady; Jean E Bestrom; Deborah J Jespersen; Mary F Jones; Elaine M Beito; Matthew J Binnicker; Nancy L Wengenack
Journal:  Med Mycol       Date:  2009-02-04       Impact factor: 4.076

2.  Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis.

Authors:  Joseph N Jarvis; Ann Percival; Sean Bauman; Joy Pelfrey; Graeme Meintjes; G Ntombomzi Williams; Nicky Longley; Thomas S Harrison; Thomas R Kozel
Journal:  Clin Infect Dis       Date:  2011-09-21       Impact factor: 9.079

3.  Comparison of two rapid latex agglutination tests for detection of cryptococcal capsular polysaccharide.

Authors:  D L Jaye; K B Waites; B Parker; S L Bragg; S A Moser
Journal:  Am J Clin Pathol       Date:  1998-05       Impact factor: 2.493

4.  Evaluation of new monoclonal antibody-based latex agglutination test for detection of cryptococcal polysaccharide antigen in serum and cerebrospinal fluid.

Authors:  D L Kiska; D R Orkiszewski; D Howell; P H Gilligan
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

5.  Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigen.

Authors:  Ann Percival; Peter Thorkildson; Thomas R Kozel
Journal:  Clin Vaccine Immunol       Date:  2011-06-22

6.  Comparison of commercial kits for detection of cryptococcal antigen.

Authors:  D C Tanner; M P Weinstein; B Fedorciw; K L Joho; J J Thorpe; L Reller
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948

7.  Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis.

Authors:  Mark D Lindsley; Nanthawan Mekha; Henry C Baggett; Yupha Surinthong; Rinrapas Autthateinchai; Pongpun Sawatwong; Julie R Harris; Benjamin J Park; Tom Chiller; S Arunmozhi Balajee; Natteewan Poonwan
Journal:  Clin Infect Dis       Date:  2011-08       Impact factor: 9.079

  7 in total
  36 in total

1.  Evaluation of the Dynamiker Cryptococcal Antigen Lateral Flow Assay for the Diagnosis of HIV-Associated Cryptococcosis.

Authors:  Richard Kwizera; Denis Omali; Kiiza Tadeo; John Kasibante; Morris K Rutakingirwa; Enock Kagimu; Kenneth Ssebambulidde; Darlisha A Williams; Joshua Rhein; David Boulware; David B Meya
Journal:  J Clin Microbiol       Date:  2021-02-18       Impact factor: 5.948

2.  Update on fungal diagnostics.

Authors:  Allen T Griffin; Kimberly E Hanson
Journal:  Curr Infect Dis Rep       Date:  2014-08       Impact factor: 3.725

3.  Evolution of Cryptococcal Antigen Testing: What is new?

Authors:  Elizabeth Nalintya; Reuben Kiggundu; David Meya
Journal:  Curr Fungal Infect Rep       Date:  2016-04-12

Review 4.  Cryptococcosis.

Authors:  Eileen K Maziarz; John R Perfect
Journal:  Infect Dis Clin North Am       Date:  2016-03       Impact factor: 5.982

5.  Low Cryptococcus Antigen Titers as Determined by Lateral Flow Assay Should Be Interpreted Cautiously in Patients without Prior Diagnosis of Cryptococcal Infection.

Authors:  Marie Dubbels; Dane Granger; Elitza S Theel
Journal:  J Clin Microbiol       Date:  2017-05-31       Impact factor: 5.948

6.  Performance of the Cryptococcal Antigen Lateral Flow Assay in Non-HIV-Related Cryptococcosis.

Authors:  Anupop Jitmuang; Anil A Panackal; Peter R Williamson; John E Bennett; John P Dekker; Adrian M Zelazny
Journal:  J Clin Microbiol       Date:  2015-11-25       Impact factor: 5.948

Review 7.  Cryptococcal infections: changing epidemiology and implications for therapy.

Authors:  Ricardo M La Hoz; Peter G Pappas
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

8.  Performance of the Lateral Flow Assay and the Latex Agglutination Serum Cryptococcal Antigen Test in Cryptococcal Disease in Patients with and without HIV.

Authors:  Matthew A Hevey; Ige A George; Adriana M Rauseo; Lindsey Larson; William Powderly; Andrej Spec
Journal:  J Clin Microbiol       Date:  2020-10-21       Impact factor: 5.948

Review 9.  Recent trends in molecular diagnostics of yeast infections: from PCR to NGS.

Authors:  Toni Gabaldón
Journal:  FEMS Microbiol Rev       Date:  2019-09-01       Impact factor: 16.408

10.  Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status.

Authors:  Sarah L Pett; Moira Spyer; Lewis J Haddow; Ruth Nhema; Laura A Benjamin; Grace Najjuka; Sithembile Bilima; Ibrahim Daud; Godfrey Musoro; Juliet Kitabalwa; George Selemani; Salome Kandie; K Magut Cornelius; Chrispus Katemba; Jay A Berkley; Amin S Hassan; Cissy Kityo; James Hakim; Robert S Heyderman; Diana M Gibb; Ann S Walker
Journal:  AIDS       Date:  2021-03-15       Impact factor: 4.632

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.